Drug Profile


Alternative Names: LU-AA24530

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lundbeck A/S
  • Developer Lundbeck A/S; Takeda
  • Class Antidepressants; Anxiolytics; Piperidines
  • Mechanism of Action Biogenic monoamine uptake inhibitors; Serotonin 2C receptor antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Generalised anxiety disorder; Major depressive disorder

Most Recent Events

  • 10 May 2016 Discontinued - Phase-I for Generalised anxiety disorder in USA, Japan (PO)
  • 10 May 2016 Discontinued - Phase-I for Major depressive disorder in USA, Japan (PO)
  • 30 Jul 2015 Tedatioxetine is still in phase I trials for Major depressive disorders and Generalised anxiety disorder in USA and Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top